Texas Compounder Warned for Sterility Practices, Other GMP Violations

Drug Industry Daily
A A
The FDA issued a warning letter to a Texas drug compounding facility after it failed to resolve problems identified during an inspection, including serious deficiencies in sterile drug processing.

To View This Article:

Login

Subscribe To Drug Industry Daily